2.70 USD
▼-0.41-13.34%
盘后 3.60 0.00%
2026-11-20
市值
$279.54M
市盈率
—
EPS
-0.71
股息率
—
52 周区间
2.65 – 8.00
成交量
1.41M
Beta
0.57
目标价
10.75
52W 低 2.6552W 高 8.00
价格走势
公司简介
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive ...